Saturday 17 October 2026
Export FLNA’s income statement to Excel — free account
Cassava Sciences, Inc.
FLNA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 80.4% and free cash flow grew 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.71
0.05
−6.58%
Follow FLNA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(85.44%) | (82.66%) | (79.59%) | (55.78%) | |
| (59.99%) | (65.95%) | (62.50%) | (35.34%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(129.80%) | (122.08%) | (114.14%) | (66.33%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.74) | (0.68) | (0.62) | (0.61) | |
Free Cash Flow |
(83.95) | (32.91) | (29.79) | (29.36) | |
Capital Expenditures |
(0.18) | (0.65) | — | (0.66) | |
| Other line items | |||||
Cash ROIC |
(44.74%) | (19.37%) | (19.26%) | (20.07%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.35 | 0.38 | 0.68 | |
Depreciation/Fixed assets |
0.04 | 0.05 | 0.05 | 0.05 | |
Capex/Depreciation |
(0.22) | (0.70) | 0.00 | (0.67) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.73) | (0.67) | (0.62) | (0.59) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates